Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Probl Endokrinol (Mosk) ; 69(1): 36-49, 2023 02 25.
Article in Russian | MEDLINE | ID: covidwho-2326023

ABSTRACT

BACKGROUND: Numerous studies indicate a high incidence of various disorders of carbohydrate metabolism against the new coronavirus infection. These disorders aggravate the course of infection and increase mortality. Thereby, analysis of risk factors for unfavorable outcomes and assessment of the long-term consequences of COVID-19 in patients with impaired carbohydrate metabolism is of great importance. AIM: To investigate the association between carbohydrate metabolism disorders in COVID-19 patients and mortality, course of infection, long-term consequences, as well as to identify risk factors for an unfavorable disease course. MATERIALS AND METHODS: A retrospective analysis of data from the combined multicenter non-interventional real-world AKTIV and AKTIV 2 registries was performed. The sample included 9290 patients who had COVID-19 with varying severity from June 29, 2020, to November 29, 2020 (AKTIV) and from October 01, 2020, to March 30, 2021 (AKTIV 2). The patients were divided into 3 groups: Group 1 - patients with intact carbohydrate metabolism, n=6606; Group 2 - patients with newly diagnosed hyperglycemia (NDH), n=1073; Group 3 - patients with a history of type 2 diabetes mellitus (DM2), n=1611. The groups were assessed for clinical and laboratory parameters, comorbidities, mortality, carbohydrate metabolic status, and well-being during the infection and at 12 months. RESULTS: The prevalence of carbohydrate metabolism disorders (CMD) was 28,9%, with DM2 patients accounting for 17,3% and patients with newly diagnosed hyperglycemia (NDH) for 11,6%. The mortality rate of patients with hyperglycemia of any origin was 10.6%, which was significantly higher compared to patients without hyperglycemia (3,9%). The probability of lethal outcome increased 2,48-fold in the group of patients with DM2 and 2,04-fold in the group of patients with NDH. At the same time, the probability of a lethal outcome decreased 2,94-fold in patients without CMD. At 12 months, patients with CMD showed a significantly higher frequency and longer persistence of complaints. This trend was more pronounced in patients with DM2 than in those with NDH. Only 1,7% of patients from the NDH group had type 2 diabetes and were receiving oral hypoglycemic medications one year after the infection. A prognostic model was developed to determine the risk of lethal outcome. The model included such known predictors as concomitant ischemic heart disease, history of myocardial infarction or stroke, blood glucose level, and age. CONCLUSION: Carbohydrate metabolism disorders aggravate the course of COVID-19 and increase mortality. One year after infection, patients with DM2 and NDH were more likely to have symptoms typical for post-COVID syndrome, and NDH resolved in most cases after the infection.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 2 , Hyperglycemia , Humans , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/epidemiology , Retrospective Studies , COVID-19/epidemiology , COVID-19/complications , Carbohydrate Metabolism , Registries
2.
Russian Archives of Internal Medicine ; 13(2):116-128, 2023.
Article in English | EMBASE | ID: covidwho-2321905

ABSTRACT

Objective. To study the course of the new coronavirus infection in patients with chronic kidney disease (CKD), to identify cases of acute kidney injury (AKI) in the setting of COVID-19 infection, and to access the impact of renal function on prognosis in these categories of patients during the acute phase and after hospitalization, at 3, 6, and 12 months after recovery. Materials and methods. The ACTIV and ACTIV 2 registries included men and women older than 18 years with a diagnosis of COVID-19 based on a positive PCR test for COVID-19 and a characteristic chest X-ray or computed tomography chest scan. Results. A total of 9364 patients (4404 men, average age59 [48-69]) were included in the analysis. 716 (7.67 %) patients had CKD. 8496 (90,7 %) patients had their glomerular filtration rate (GFR) measured during hospitalization, and the values were distributed as follows: >=90 ml/min/1.73m2 - in 4289 (50,5 %) patients, 89-60 ml/min/1.73m2 - in 3150 (37,1 %) patients, 59-45 ml/min/1.73m2 - in 613 (7,22 %), 44-30 ml/min/1.73m2 - in 253 (2,98 %), 29-15 ml/min/1.73m2 - in 110 (1,29 %), <15 ml/min/1.73m2 - in 81 (0,95 %) patients. 11.6 % of the subjects (n=1068) developed AKI during hospitalization. This complication was reported more often than cytokine storm (in 7.46 % in 687 patients, p<0,001) or sepsis (in 0.17 % in 16 patients, p=620). CKD increased the risk of death by 3.94-fold in patients with COVID-19 during hospitalization compared with patients without CKD. The mortality of patients with AKI during hospitalization was 3.94 times higher than the mortality of those without AKI. CKD also affected long-term survival after hospitalization: within 3 months of follow-up, the risk of death in patients with CKD increased 4.88-fold, within 6 months - 4.24-fold, after 12 months - 8.36-fold. Conclusion. The prevalence of CKD in COVID-19 patients is similar to that in the general population. AKI developed in 11.6 % of cases with COVID-19 infection and was observed more frequently in patients with overweight and hyperglycemia. CKD and AKI increased the risk of hospital mortality in patients with COVID-19. In the group of patients with CKD, mortality increased in the post-COVID period, 3, 6 and 12 months after. The high mortality rate of patients who had AKI during the coronavirus infection was observed only in the first 3 months of follow-up in the post-COVID period.Copyright © 2023 The authors.

3.
ESC Heart Fail ; 10(2): 1013-1024, 2023 04.
Article in English | MEDLINE | ID: covidwho-2250288

ABSTRACT

AIMS: To study all-cause mortality in patients hospitalized with COVID-19 with or without chronic heart failure (CHF) during hospitalization and at 3 and 6 months of follow-up. METHODS AND RESULTS: The international registry Analysis of Comorbid Disease Dynamics in Patients with SARS-CoV-2 Infection (ACTIV) was conducted at 26 centres in seven countries: Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russian Federation, and Uzbekistan. The primary endpoints were in-hospital all-cause mortality and all-cause mortality at 3 and 6 months of follow-up. Of the 5616 patients hospitalized with COVID-19, 917 (16.3%) had CHF. Total in-hospital mortality was 7.6%. In-hospital mortality was higher in patients with CHF than in patients without a history of CHF [17.7% vs. 4.0%, P < 0.001; odds ratio (OR) 4.614, 95% confidence interval (CI) 3.633-5.859; P < 0.001]. The risk of in-hospital all-cause mortality correlated significantly with the severity of CHF; specifically, the risk of in-hospital all-cause mortality was greater for patients in New York Heart Association functional classes III and IV (OR 6.124, 95% CI 4.538-8.266; P < 0.001 vs. patients without CHF) than for patients in functional classes I and II (OR 2.446, 95% CI 1.831-3.267, P < 0.001 vs. patients without CHF). The risk of mortality in patients with ischemic CHF was 58% higher than in patients with non-ischaemic CHF [OR 1.58 (95% CI 1.05-2.45), P = 0.030]. In the first 3 months of follow-up, the all-cause mortality rate in patients with CHF was 10.32%, compared with 1.83% in patients without CHF (P < 0.001). At 6 months of follow-up, NYHA classes II-IV was a strong risk factor for all-cause mortality [OR 5.343 (95% CI 2.717-10.508); P < 0.001]. CONCLUSIONS: Hospitalized COVID-19 patients with CHF have an increased risk of in-hospital all-cause mortality, which remains high 6 months after discharge.


Subject(s)
COVID-19 , Heart Failure , Humans , COVID-19/complications , SARS-CoV-2 , Heart Failure/complications , Hospitalization , Registries
4.
Kardiologiia ; 62(12): 38-49, 2022 Dec 31.
Article in Russian | MEDLINE | ID: covidwho-2250287

ABSTRACT

Цель:  Ð˜Ð·ÑƒÑ‡ÐµÐ½Ð¸Ðµ особенностей клинического течения новой коронавирусной инфекции и  влияния сопутствующих заболеваний на исход заболевания у госпитализированных больных с инфекцией SARS-CoV-2 в первую и вторую волны пандемии.Методы и результаты.  Для оценки особенностей течения COVID-19 в Евразийском регионе были созданы международные регистры АКТИВ 1 и во время второй волны пандемии АКТИВ 2. Набор больных в регистр АКТИВ 1 проводили с 29.06.20 по 29.10.20, набрано 5 397 пациентов. Прием пациентов на учет в АКТИВ 2 проводили с 01.11.20 до 30.03.21, набрано 2 665 больных.Результаты. Госпитальная летальность снизилась в  Ð¿ÐµÑ€Ð¸Ð¾Ð´ второй волны пандемии и  ÑÐ¾ÑÑ‚Ð°Ð²Ð¸Ð»Ð° 4,8 % против 7,6 % в  Ð¿ÐµÑ€Ð¸Ð¾Ð´ первой волны. В  Ð¿ÐµÑ€Ð¸Ð¾Ð´ второй волны пациенты были старше, имели больше сопутствующих заболеваний и поступали в стационар в более тяжелом состоянии, пациенты имели более высокий уровень полиморбидности. В период второй волны пандемии увеличилась заболеваемость бактериальной пневмонией и сепсисом, но реже встречались тромбозы глубоких вен и «Ñ†Ð¸Ñ‚Ð¾ÐºÐ¸Ð½Ð¾Ð²Ñ‹Ð¹ шторм¼. Наиболее неблагоприятными для прогноза смертности, как в первую, так и во вторую волны эпидемии были сочетания сопутствующих заболеваний: артериальная гипертензия (АГ) + хроническая сердечная недостаточность (ХСН) + сахарный диабет (СД) + ожирение, АГ + ишемическая болезнь сердца (ИБС) + ХСН + СД, АГ + ИБС + ХСН + ожирение.Заключение. Ð£ пациентов во вторую волну пандемии наблюдалось более обширное поражение ткани легких, чаще возникала фебрильная лихорадка, были выше уровни С-реактивного белка и  Ñ‚Ñ€Ð¾Ð¿Ð¾Ð½Ð¸Ð½Ð°, ниже уровни гемоглобина и лимфоцитов. Это, вероятно, связано с различной тактикой госпитализации пациентов в первую и вторую волны пандемии в странах, принявших участие в формировании регистров АКТИВ 1 и АКТИВ 2.


Subject(s)
COVID-19 , Irritable Bowel Syndrome , Humans , Pandemics , SARS-CoV-2
5.
Probl Endokrinol (Mosk) ; 68(6): 89-109, 2023 Jan 24.
Article in Russian | MEDLINE | ID: covidwho-2250285

ABSTRACT

BACKGROUND: There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI). AIM: To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period. MATERIALS AND METHODS: AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected  the  data  of  hospitalized  patients  and  included  3  visits.  All  subjects  were  divided  into  3  groups:  not  overweight  (n=2139), overweight (n=2931) and obese (n=2666). RESULTS: A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (p<0.001), serum C-reactive protein over 100 mg/l (p<0.001), and the need for targeted therapy (p<0.001) in the hospitalized patients. Obesity increased the odds of myocarditis by 1,84 times (95% confidence interval [CI]: 1,13-3,00) and the need for anticytokine therapy by 1,7 times (95% CI: 1,30-2,30).The  patients  with  the  1st  and  2nd  degree  obesity,  undergoing  the  inpatient  treatment,  tended  to  have  a  higher  probability  of  a  mortality  rate.  While  in  case  of  morbid  obesity  patients  this  tendency  is  the  most  significant  (odds  ratio  -  1,78; 95% CI: 1,13-2,70). At the same time, the patients whose chronical diseases first appeared after the convalescence period, and those who had certain complaints missing before SARS-CoV-2 infection, more often had BMI of more than 30 kg/m2 (p<0,001).Additionally, the odds of death increased by 2,23 times (95% CI: 1,05-4,72) within 3 months after recovery in obese people over the age of 60 yearsCONCLUSION.  Overweight  and/or  obesity  is  a  significant  risk  factor  for severe  course  of  the  new  coronavirus  infection  and  the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.


Subject(s)
COVID-19 , Humans , Middle Aged , SARS-CoV-2 , Body Mass Index , Patient Discharge , Overweight , Hospitals , Obesity
6.
Arterial Hypertension (Russian Federation) ; 28(4):464-476, 2022.
Article in Russian | EMBASE | ID: covidwho-2266985

ABSTRACT

On December 1, 2021, a meeting of the Council of experts on the treatment of hypertension, coronary heart disease, and chronic heart failure during the COVID-19 pandemic was held remotely to adjust and adapt current approaches to outpatient treatment of the above pathologies under the current epidemiological situation. The meeting was attended by leading Russian specialists from federal medical research centers of cardiology and therapy.Copyright © 2022 All-Russian Public Organization Antihypertensive League. All rights reserved.

7.
Arterial Hypertension (Russian Federation) ; 28(4):464-476, 2022.
Article in Russian | EMBASE | ID: covidwho-2217821

ABSTRACT

On December 1, 2021, a meeting of the Council of experts on the treatment of hypertension, coronary heart disease, and chronic heart failure during the COVID-19 pandemic was held remotely to adjust and adapt current approaches to outpatient treatment of the above pathologies under the current epidemiological situation. The meeting was attended by leading Russian specialists from federal medical research centers of cardiology and therapy. Copyright © 2022 All-Russian Public Organization Antihypertensive League. All rights reserved.

8.
Eksperimental'naya i Klinicheskaya Farmakologiya ; 85(3):13-20, 2022.
Article in Russian | EMBASE | ID: covidwho-2156121

ABSTRACT

Under auspices of the Eurasian Association of Therapists (EUAT), a Council of Experts (COE) was organized to develop criteria for the timing of administration (day of illness onset) of COVID-globulin, dosing regimens and patient phenotypes depending on comorbid pathology to optimize indications and achieve maximum effectiveness of virus-neutralizing therapy. The need for COE creation is related to the lack of criteria based on large-scale evidence-based studies. That is why the working group of COE includes experts in all fields of internal medicine, in particular, transfusiology specialists. The COE activity was held with the participation of largest plasma transfusion centers for recuperative patients including Clinical Hospitals No. 40 and 52 of the Moscow City Government Department of Health, and the N. V. Sklifosovsky Institute of Emergency Medicine. Copyright © 2022 Authors. All rights reserved.

9.
Russian Journal of Cardiology ; 26(10):86-98, 2021.
Article in Russian | EMBASE | ID: covidwho-2145624

ABSTRACT

Aim. To study the clinical course specifics of coronavirus disease 2019 (COVID-19) and comorbid conditions in COVID-19 survivors 3, 6, 12 months after recovery in the Eurasian region according to the AKTIV register. Material and methods. The AKTIV register was created at the initiative of the Eurasian Association of Therapists. The AKTIV register is divided into 2 parts: AKTIV 1 and AKTIV 2. The AKTIV 1 register currently includes 6300 patients, while in AKTIV 2 - 2770. Patients diagnosed with COVID-19 receiving in-and outpatient treatment have been anonymously included on the registry. The following 7 countries participated in the register: Russian Federation, Republic of Armenia, Republic of Belarus, Republic of Kazakhstan, Kyrgyz Republic, Republic of Moldova, Republic of Uzbekistan. This closed multicenter register with two non-overlapping branches (in-and outpatient branch) provides 6 visits: 3 in-person visits during the acute period and 3 telephone calls after 3, 6, 12 months. Subject recruitment lasted from June 29, 2020 to October 29, 2020. Register will end on October 29, 2022. A total of 9 fragmentary analyzes of the registry data are planned. This fragment of the study presents the results of the post-hospitalization period in COVID-19 survivors after 3 and 6 months. Results. According to the AKTIV register, patients after COVID-19 are characterized by long-term persistent symptoms and frequent seeking for unscheduled medical care, including rehospitalizations. The most common causes of unplanned medical care are uncontrolled hypertension (HTN) and chronic coronary artery disease (CAD) and/or decompensated type 2 diabetes (T2D). During 3-and 6-month follow-up after hospitalization, 5,6% and 6,4% of patients were diagnosed with other diseases, which were more often presented by HTN, T2D, and CAD. The mortality rate of patients in the post-hospitalization period was 1,9% in the first 3 months and 0,2% for 4-6 months. The highest mortality rate was observed in the first 3 months in the group of patients with class II-IV heart failure, as well as in patients with cardiovascular diseases and cancer. In the pattern of death causes in the post-hospitalization period, following cardiovascular causes prevailed (31,8%): acute coronary syndrome, stroke, acute heart failure. Conclusion. According to the AKTIV register, the health status of patients after COVID-19 in a serious challenge for healthcare system, which requires planning adequate health system capacity to provide care to patients with COVID-19 in both acute and post-hospitalization period. Copyright © 2021, Silicea-Poligraf. All rights reserved.

10.
Russian Journal of Cardiology ; 26(9):135-151, 2021.
Article in Russian | EMBASE | ID: covidwho-2113942

ABSTRACT

By the middle of 2021, the official global number of coronavirus disease 2019 (COVID-19) patients was close to 230 million, but the number accounting for asymptomatic patients was much higher. Consequences and rehabilitation after COVID-19 are of particular interest and raise many controversial and unresolved issues. On May 18, 2021, the Eurasian Association of Therapists organized an international panel of experts to analyze challenges associated with the post-COVID-19 period. This panel aimed to develop approaches to identify gaps in the discussed issues. This interdisciplinary team of leading experts reviewed the current literature and presented their data to formulate practical guidance on management of patients after COVID-19. The panel of experts also presented recommendations on how to implement the gained knowledge into health care practices. Copyright © 2021, Silicea-Poligraf. All rights reserved.

11.
Cardiovascular Journal of Africa ; 33(Supplement):63-64, 2022.
Article in English | EMBASE | ID: covidwho-2072763

ABSTRACT

Introduction Cardiovascular disease may adversely affect the incidence rate, severity of acute infection and post-covid period, and mortality rate associated with the new coronavirus infection. Methods An international registry ACTIV SARS-CoV-2 was established to evaluate the course of COVID-19 and involved experts from 7 countries (ClinicalTrials.gov: NCT04492384). The course of the acute period was assessed using data from 5808 patients. The course of post-covid period was assessed using the results of telephone calls to 2185 patients 3 months after recovery and to 1208 patients 6 months after recovery. Results 55.41% of the patients had arterial hypertension (AH) when they acquired the infection and were more likely to require in-hospital treatment (60.85% vs. 30.84% outpatients, p<0.001). AH in COVID-19 patients increased the mortality odds ratio both in the acute and the post-covid period. The mortality odds ratio was higher in patients over 60 and with multiple chronic comorbidities (Table 1). Increased BP over prior effective antihypertensive treatment was reported in 18.6% and 19.1% of patients in 3 and 6 months, respectively. Uncontrolled AH was the most common cause of medical care encounters (40.2% and 37.1%, respectively). AH accounted for 41.5% and 46.7% of the newly diagnosed conditions during 3- and 6-months follow-up, respectively. Conclusion AH increased hospitalization rate and negatively impacted the prognosis of the acute period in hospitalized COVID-19 patients and their prognosis during the first 3 months after recovery. The mortality risk increased in the patients over 60 and with several chronic conditions. AH was the most common newly diagnosed condition in the post-covid period. The presented data should be taken into account when planning prevention, treatment, and rehabilitation for COVID-19 patients.

12.
Russian Journal of Cardiology ; 27(3):9-17, 2022.
Article in Russian | EMBASE | ID: covidwho-1822635

ABSTRACT

Aim. To carry out comparative analysis of echocardiographic and electrocardiographic (ECG) data of survivors and deceased patients with COVID-19 (sub-analysis of the international register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors”). Material and methods. The study presents the results of a sub-analysis of the international AKTIV registry, which was called AKTIV CARDIO. Data were collected from 9 medical centers in the Russian Federation. AKTIV CARDIO included 973 hospitalized patients, of which 50 patients died during hospitalization. Results. Comparative analysis of echocardiographic parameters revealed that 4 parameters differed in deceased patients compared to survivors: left ventricular ejection fraction (LVEF), right ventricular end diastolic dimension (RV EDD), right atrial (RA) short axis diameter and pulmonary artery systolic pressure (PASP). RA short axis diameter was higher in deceased patients compared with survivors (38,0 [36,0;39,0] versus 35,0 [33,0;38,0] mm, p=0,011). RV EDD was higher in deceased patients than in survivors (3,0 [29,0;33,0] vs 28,0 [27,0;32,0] mm, p=0,019). LVEF was lower in deceased patients compared with survivors (55 [52;55] vs 60 [56;65]%, p<0,001). PASP was higher in deceased patients compared with survivors (25 [21;35] vs 20 [19;25] mm Hg, p=0,006). Correlation analysis found that the largest number of correlations with markers of the infection severity was observed for RA short axis diameter and RV EDD. A comparative analysis of ECG data revealed that in deceased patients, compared with survivors, atrial fibrillation (AF) (21,4% vs 6,06%, p=0,001) and supraventricular premature beats (14,3% vs 3,36%, р=0,004) occurred more often. In addition, deceased patients had longer QTc interval (440 [416;450] vs 400 [380;430] ms, p<0,001). Conclusion. Comparative analysis of echocardiographic data showed that deceased patients have more pronounced right heart remodeling, higher PASP and lower LVEF. Patient survival was related to RV and RA sizes. Right heart enlargement was associated with markers of infection severity. Echocardiographic parameters characterizing the right heart side can probably be independent prognostic factors in the acute COVID-19 period.

13.
Ter Arkh ; 94(1): 32-47, 2022 Jan 15.
Article in Russian | MEDLINE | ID: covidwho-1798590

ABSTRACT

AIM: Study the impact of various combinations of comorbid original diseases in patients infected with COVID-19 later on the disease progression and outcomes of the new coronavirus infection. MATERIALS AND METHODS: The ACTIV registry was created on the Eurasian Association of Therapists initiative. 5,808 patients have been included in the registry: men and women with COVID-19 treated at hospital or at home. CLINICALTRIALS: gov ID NCT04492384. RESULTS: Most patients with COVID-19 have original comorbid diseases (oCDs). Polymorbidity assessed by way of simple counting of oCDs is an independent factor in negative outcomes of COVID-19. Search for most frequent combinations of 2, 3 and 4 oCDs has revealed absolute domination of cardiovascular diseases (all possible variants). The most unfavorable combination of 2 oCDs includes atrial hypertension (AH) and chronic heart failure (CHF). The most unfavorable combination of 3 oCDs includes AH, coronary heart disease (CHD) and CHF; the worst combination of 4 oCDs includes AH, CHD, CHF and diabetes mellitus. Such combinations increased the risk of lethal outcomes 3.963, 4.082 and 4.215 times respectively. CONCLUSION: Polymorbidity determined by way of simple counting of diseases may be estimated as a factor in the lethal outcome risk in the acute phase of COVID-19 in real practice. Most frequent combinations of 2, 3 and 4 diseases in patients with COVID-19 primarily include cardiovascular diseases (AH, CHD and CHF), diabetes mellitus and obesity. Combinations of such diseases increase the COVID-19 lethal outcome risk.


Subject(s)
COVID-19 , Cardiovascular Diseases , Coronary Disease , Diabetes Mellitus , Heart Failure , Hypertension , Noncommunicable Diseases , Adult , Female , Humans , Male , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Chronic Disease , COVID-19/diagnosis , COVID-19/epidemiology , Hypertension/diagnosis , Hypertension/epidemiology , Prognosis , Registries , SARS-CoV-2
14.
Pulmonologiya ; 31(5):599-612, 2021.
Article in Russian | Scopus | ID: covidwho-1631173

ABSTRACT

The post-COVID symptom complex is wide enough and requires special vigilance during clinical examination of patients after the novel coronavirus infection. The aim of the Multidisciplinary Expert Board study was to develop a standardized questionnaire for initial self-assessment by patients who had had COVID-19 before the expanded medical check-up. Methods. The existing validated international and national questionnaires and scales were analyzed to assess their relevance, convenience, and ease of filling out. Results of the analysis were used to set up a screening for post-COVID symptoms. Results. The work of the Multidisciplinary Expert Board in June-August 2021 resulted in a new screening questionnaire for the initial assessment of the health status of patients who have COVID-19. The questionnaire is intended for self-filling before the further clinical examination. Conclusion. A new standardized patient questionnaire to screen for post-COVID symptoms may significantly optimize the doctor’s working time, increase the efficiency of diagnosis, improve the principles of selection and formation of risk groups of patients during an expanded medical check-up. © 2021 Medical Education. All rights reserved.

15.
Kardiologiia ; 61(9): 20-32, 2021 Sep 30.
Article in Russian, English | MEDLINE | ID: covidwho-1527055

ABSTRACT

Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features). The register territory included 7 countries: the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan. The registry design: a closed, multicenter registry with two nonoverlapping arms (outpatient arm and in-patient arm). The registry scheduled 6 visits, 3 in-person visits during the acute period and 3 virtual visits (telephone calls) at 3, 6, and 12 mos. Patient enrollment started on June 29, 2020 and was completed on October 29, 2020. The registry completion is scheduled for October 29, 2022. The registry ID: ClinicalTrials.gov: NCT04492384. In this fragment of the study of registry data, the work group analyzed the effect of therapy for comorbidities at baseline on severity and outcomes of the novel coronavirus infection. The study population included only the patients who took their medicines on a regular basis while the comparison population consisted of noncompliant patients (irregular drug intake or not taking drugs at all despite indications for the treatment).Results The analysis of the ACTIVE registry database included 5808 patients. The vast majority of patients with COVID-19 had comorbidities with prevalence of cardiovascular diseases. Medicines used for the treatment of COVID-19 comorbidities influenced the course of the infectious disease in different ways. A lower risk of fatal outcome was associated with the statin treatment in patients with ischemic heart disease (IHD); with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists and with beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation; with oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD; with oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM); and with long-acting insulins in patients with type 1 DM. A higher risk of fatal outcome was associated with the spironolactone treatment in patients with CHF and with inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD).Conclusion      In the epoch of COVID-19 pandemic, a lower risk of severe course of the coronavirus infection was observed for patients with chronic noninfectious comorbidities highly compliant with the base treatment of the comorbidity.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 2 , Noncommunicable Diseases , Adult , Comorbidity , Female , Humans , Male , Pandemics , Registries , SARS-CoV-2
16.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Rebrov, A. P.; Tereshchenko, S. N.; Chesnikova, A. I.; Hayrapetyan, H. G.; Babin, A. P.; Bakulin, I. G.; Bakulina, N. V.; Balykova, L. A.; Blagonravova, A. S.; Boldina, M. V.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigorieva, N. U.; Gubareva, I. V.; Demko, I. V.; Evzerikhina, A. V.; Zharkov, A. V.; Kamilova, U. K.; Kim, Z. F.; Kuznetsova, T. Yu, Lareva, N. V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Petrova, M. M.; Pochinka, I. G.; Protasov, K. V.; Protsenko, D. N.; Ruzanov, D. Yu, Sayganov, S. A.; Sarybaev, A. Sh, Selezneva, N. M.; Sugraliev, A. B.; Fomin, I. V.; Khlynova, O. V.; Chizhova, O. Yu, Shaposhnik, I. I.; Sсhukarev, D. A.; Abdrahmanova, A. K.; Avetisian, S. A.; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch, Alieva, M. K.; Aparkina, A. V.; Aruslanova, O. R.; Ashina, E. Yu, Badina, O. Y.; Barisheva, O. Yu, Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Vezikova, N. N.; Verbitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Gаlova, E. A.; Genkel, V. V.; Gorshenina, E. I.; Gostishev, R. V.; Grigorieva, E. V.; Gubareva, E. Yu, Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu, Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K. E.; Ermilova, A. N.; Zheldybayeva, A. E.; Zarechnova, N. V.; Ivanova, S. Yu, Ivanchenko, E. Yu, Ilina, M. V.; Kazakovtseva, M. V.; Kazymova, E. V.; Kalinina, Y. S.; Kamardina, N. A.; Karachenova, A. M.; Karetnikov, I. A.; Karoli, N. A.; Karpov, O. V.; Karsiev, M. Kh, Кaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Z. B.; Kerimova, A. Sh, Kim, E. S.; Kiseleva, N. V.; Klimenko, D. A.; Klimova, A. V.; Kovalishena, O. V.; Kolmakova, E. V.; Kolchinskaya, T. P.; Kolyadich, M. I.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu, Konstantinova, E. A.; Kordukova, V. A.; Koroleva, E. V.; Kraposhina, A. Yu, Kriukova, T. V.; Kuznetsova, A. S.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kulchoroeva, C. K.; Kuprina, T. V.; Kouranova, I. M.; Kurenkova, L. V.; Kurchugina, N. Yu, Kushubakova, N. A.; Levankova, V. I.; Levin, M. E.; Lyubavina, N. A.; Magdeyeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Maripov, A. M.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F. N.; Muradyan, R. G.; Musaelian, S. N.; Nikitina, N. M.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Y. M.; Omurzakova, N. A.; Ospanova, S. O.; Pahomova, E. V.; Petrov, L. D.; Plastinina, S. S.; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Pudova, I. A.; Rakov, N. A.; Rakhimov, A. N.; Rozanova, N. A.; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, I. A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D. R.; Titojkina, Y. V.; Tikhonova, E. P.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Tulichev, A. A.; Tupitsin, D. I.; Tursunova, A. T.; Ulanova, N. D.; Fatenkov, O. V.; Fedorishina, O. V.; Fil, T. S.; Fomina, I. Yu, Fominova, I. S.; Frolova, I. A.; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, M. B.; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, O. A.; Sheshina, T. V.; Shishkina, E. A.; Shishkov, K. Yu, Sherbakov, S. Y.; Yausheva, E. A..
Russian Journal of Cardiology ; 26(4):116-131, 2021.
Article in Russian | EMBASE | ID: covidwho-1488885

ABSTRACT

The international AKTIV register presents a detailed description of out-and inpatients with COVID-19 in the Eurasian region. It was found that hospitalized patients had more comorbidities. In addition, these patients were older and there were more men than among outpatients. Among the traditional risk factors, obesity and hypertension had a significant negative effect on prognosis, which was more significant for patients 60 years of age and older. Among comorbidities, CVDs had the maximum negative effect on prognosis, and this effect was more significant for patients 60 years of age and older. Among other comorbidities, type 2 and 1 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, cancer and anemia had a negative impact on the prognosis. This effect was also more significant (with the exception of type 1 diabetes) for patients 60 years and older. The death risk in patients with COVID-19 depended on the severity and type of multimorbidity. Clusters of diseases typical for deceased patients were identified and their impact on prognosis was determined. The most unfavorable was a cluster of 4 diseases, including hypertension, coronary artery disease, heart failure, and diabetes mellitus. The data obtained should be taken into account when planning measures for prevention (vaccination priority groups), treatment and rehabilitation of COVID-19 survivors.

17.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Rebrov, A. P.; Tereshchenko, S. N.; Che Snikova, A. I.; Hayrapetyan, H. G.; Babin, A. P.; Bakulin, I. G.; Bakulina, N. V.; Balykova, L. A.; Blagonravova, A. S.; Boldina, M. V.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigorieva, N. U.; Gubareva, I. V.; Demko, I. V.; Evzerikhina, A. V.; Zharkov, A. V.; Kamilova, U. K.; Kim, Z. F.; Kuznetsova, T. Yu, Lareva, N. V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Petrova, M. M.; Pochinka, I. G.; Protasov, K. V.; Protsenko, D. N.; Ruzanov, D. Yu, Sayganov, S. A.; Sarybaev, A. Sh, Selezneva, N. M.; Sugraliev, A. B.; Fomin, I. V.; Khlynova, O. V.; Chizhova, O. Yu, Shaposhnik, I. I.; Sсhukarev, D. A.; Abdrahmanova, A. K.; Avetisian, S. A.; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch, Alieva, M. K.; Aparkina, A. V.; Aruslanova, O. R.; Ashina, E. Yu, Badina, O. Y.; Barisheva, O. Yu, Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Vezikova, N. N.; Ver Bitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Gаlova, E. A.; Genkel, V. V.; Gorshenina, E. I.; Gostishev, R. V.; Grigorieva, E. V.; Gubareva, E. Yu, Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu, Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K. E.; Ermilova, A. N.; Zheldybayeva, A. E.; Zarechnova, N. V.; Ivanova, S. Yu, Ivanchenko, E. Yu, Ilina, M. V.; Kazakovtseva, M. V.; Kazymova, E. V.; Kalinina, Yu S.; Kamardina, N. A.; Karachenova, A. M.; Karetnikov, I. A.; Karoli, N. A.; Karpov, O. V.; Karsiev, M. Kh, Кaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Zh B.; Kerimova, A. Sh, Kim, E. S.; Kiseleva, N. V.; Klimenko, D. A.; Klimova, A. V.; Kovalishena, O. V.; Kolmakova, E. V.; Kolchinskaya, T. P.; Kolyadich, M. I.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu, Konstantinova, E. A.; Kordukova, V. A.; Koroleva, E. V.; Kraposhina, A. Yu, Kriukova, T. V.; Kuznetsova, A. S.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kulchoroeva, Ch K.; Kuprina, T. V.; Kouranova, I. M.; Kurenkova, L. V.; Kurchugina, N. Yu, Kushubakova, N. A.; Levankova, V. I.; Levin, M. E.; Lyubavina, N. A.; Magdeyeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Maripov, A. M.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F. N.; Muradyan, R. G.; Musaelian, Sh N.; Nikitina, N. M.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Yu M.; Omurzakova, N. A.; Ospanova, Sh O.; Pahomova, E. V.; Petrov, L. D.; Plastinina, S. S.; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Pudova, I. A.; Rakov, N. A.; Rakhimov, A. N.; Rozanova, N. A.; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, I. A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D. R.; Titojkina, Y. V.; Tikhonova, E. P.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Tulichev, A. A.; Tupitsin, D. I.; Tursunova, A. T.; Tiurin, A. A.; Ulanova, N. D.; Fatenkov, O. V.; Fedorishina, O. V.; Fil, T. S.; Fomina, I. Yu, Fominova, I. S.; Frolova, I. A.; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, M. B.; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, O. A.; Sheshina, T. V.; Shishkina, E. A.; Shishkov, K. Yu, Sherbakov, S. Y.; Yausheva, E. A..
Russian Journal of Cardiology ; 26(3):102-113, 2021.
Article in Russian | EMBASE | ID: covidwho-1488882

ABSTRACT

The organizer of the registers “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV) and “Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2 outbreak” (AKTIV 2) is the Eurasian Association of Therapists (EAT). Currently, there are no clinical registries in the Eurasian region designed to collect and analyze information on long-term outcomes of COVID-19 survivors with comorbid conditions. The aim of the register is to assess the impact of a novel coronavirus infection on long-term course of chronic non-communicable diseases 3, 6, 12 months after recovery, as well as to obtain information on the effect of comorbidity on the severity of COVID-19. Analysis of hospitalized patients of a possible second wave is planned for register “AKTIV 2”. To achieve this goal, the register will include men and women over 18 years of age diagnosed with COVID-19 who are treated in a hospital or in outpatient basis. The register includes 25 centers in 5 federal districts of the Russian Federation, centers in the Republic of Armenia, the Republic of Kazakhstan, the Republic of Kyrgyzstan, the Republic of Belarus, the Republic of Moldova, and the Republic of Uzbekistan. The estimated capacity of the register is 5400 patients.

18.
Russian Journal of Cardiology ; 26(1):99-104, 2021.
Article in Russian | EMBASE | ID: covidwho-1488881

ABSTRACT

The potential impact on cardiovascular morbidity and mortality have become one of the most important issues of the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 may be associated with more frequent development of acute cardiovascular complications, while patients with established cardiovascular diseases are characterized by a higher risk of severe infection and adverse in-hospital outcomes. Due to the spread scale of the pandemic, understanding the long-term cardiovascular consequences of COVID-19 is of no less importance. Inability to extrapolate available international data to the Russian population has led to the initiation of a national multicenter study (registry) of patients recovered from COVID-19 and with concomitant involvement of the cardiovascular system or with baseline severe cardiovascular diseases. The article presents its rationale, design and implications of the results for clinical practice.

19.
Klinicheskaya nefrologiya ; 12(4):36-42, 2020.
Article in Russian | Russian Science Citation Index | ID: covidwho-1094562

ABSTRACT

Objective. evaluation of the effect of the presence of chf and/or ckd or their symptoms in patients on the incidence and/or mortality from sars-cov-2. Materials and methods. a retrospective case-control study was conducted, and 165 patients were included in the final analysis. For statistical processing of the data obtained, the R language and the RStudio software environment was used. results. only 18 of all the patients included had covid-19. by the method of cluster analysis, all patients were divided into three clusters: the first one included 53.9% of patients, the second one - 21.2% and the third one - 24.8%. patients with covid were included in the first cluster (12 patients), in the second cluster there was only 1 patient with covid, in the third - 5 (X-squared = 3.1, df = 2, p value = o.22). cluster з was characterized by changes echo-cg indices, demonstrating higher values of esv, edd, lvpw, ivs and lower ef than in other clusters (patients with severe chf). cluster 2 was characterized by a lower gfr throughout the entire follow-up period, as well as negative dynamics of gfr (45 [38, 35;57, 65] ml/ min) during the year (patients with severe ckd). cluster 1 was represented by remaining patients. assessment of the symptoms (dyspnea, edema, bendopnea, ascites) in the studied cohort of patients revealed significant differences only in the presence of the symptom of bendopnea (P value = o.015), and the odds ratio of covid-19 was higher in the group of patients with symptom of bendopnea (OR = 5,8 (1.2;26.7). Conclusion. Thus, despite the high potential risk of illness and/or death from covid-19 in clusters 3 and 2 (i.e., the group of patients with severe chf and ckd, respectively), no increase in morbidity and/or mortality from covid-19 was revealed. on the contrary, the covid incidence in cluster 1, which included patients with more favorable clinical indicators of chf and ckd, was higher, but did not reach the statistical significance (P = o.222). apparently, it was attributable to the greater mobility of patients in this category as compared to patients in clusters 2 and 3. Цель исследования: изучить влияние наличия у пациентов с хсн и/или хбп или их симптомов на частоту заболеваемости и/или смертности от sars-cov-2. Материалы и методы. Проведено ретроспективное исследование случай-контроль. в окончательный анализ были включены 165 пациентов. Для статистической обработки полученных данных использовали язык R, программную среду RStudio. Результаты. Из всех включенных пациентов, только 18 переболели COV1D-19. Методом кластерного анализа все пациенты были разделены на три кластера: 1-й составил 53,9% пациентов, 2-й - 21,2% и 3-й - 24,8%. пациенты, перенесшие covid, попали в первый кластер (12 пациентов), во втором кластере оказался всего 1 пациент, в третьем - 5 (x-squared=3,1, df=2, p-value=0,22). Для кластера 3 характерны изменения показателей Эхо-КГ сердца, продемонстрировавшие более высокие значения ксо, кдр, зс, мжп и более низкую фв, чем в других кластерах (пациенты с тяжелой хсн). для кластера 2 характерна более низкая скф на протяжении всего периода наблюдения, а также отрицательная динамика показателей скф (45 [38, 35;57, 65] мин/мин) в течение года (пациенты с тяжелой хбп). первый кластер представлен остальными пациентами. Изучая симптомы (одышка, отеки, бендопноэ, асцит) у изучаемой когорты пациентов, были найдены значимые различия только в наличии симптома бендопноэ (p-value=0,015), и шанс заболевания covid-19 был выше в группе пациентов с симптомом бендопноэ (0Ш=5,8 (1,2;26,7). Заключение. Таким образом, несмотря на высокий потенциальный риск заболевания и/или смерти от covid-19 в кластерах 3 и 2 (т.е. группы тяжелых пациентов с выраженной сердечной недостаточность и хбп соответственно) увеличения заболеваемости и/или смертности от covid-19 выявлено не было. напротив, частота заболеваемости в кластере 1, который по основным показателям включил пациентов с более благоприятными клиническими показателями, была выше, однако это не достигло статистической значимости, p=0,222. По-видимому, это связано с большей мобильностью пациентов данной категории пациентов по сравнению с пациентами кластеров 2 и 3.

20.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Tereshchenko, S. N.; Rebrov, A. P.; Chesnikova, A. I.; Fomin, I. V.; Grigorieva, N. U.; Boldina, M. V.; Vaisberg, A. R.; Blagonravova, A. S.; Makarova, E. V.; Shaposhnik, I. I.; Kuznetsova, T. Yu, Malchikova, S. V.; Protsenko, D. N.; Evzerikhina, A. V.; Petrova, M. M.; Demko, I. V.; Safonov, D. V.; Hayrapetyan, H. G.; Galyavich, A. S.; Kim, Z. F.; Sugraliev, A. B.; Nedogoda, S. V.; Tsoma, V. V.; Sayganov, S. A.; Gomonova, V. V.; Gubareva, I. V.; Sarybaev, A. Sh, Koroleva, E. V.; Vilkova, O. E.; Fomina, I. Y.; Pudova, I. A.; Soloveva, D. V.; Kiseleva, N. V.; Zelyaeva, N. V.; Kouranova, I. M.; Pogrebetskaya, V. A.; Muradova, F. N.; Badina, O. Y.; Kovalishena, O. V.; Galova, E. A.; Plastinina, S. S.; Lyubavina, N. A.; Vezikova, N. N.; Levankova, V. I.; Ivanova, S. Yu, Ermilova, A. N.; Muradyan, R. G.; Gostishev, R. V.; Tikhonova, E. P.; Kuzmina, T. Y.; Soloveva, I. A.; Kraposhina, A. Yu, Kolyadich, M. I.; Kolchinskaya, T. P.; Genkel, V. V.; Kuznetsova, A. S.; Kazakovtseva, M. V.; Odegova, A. A.; Chudinovskikh, T. I.; Baramzina, S. V.; Rozanova, N. A.; Kerimova, A. Sh, Krivosheina, N. A.; Chukhlova, S. Y.; Levchenko, A. A.; Avoyan, H. G.; Azarian, K. K.; Musaelian, Sh N.; Avetisian, S. A.; Levin, M. E.; Karpov, O. V.; Sokhova, F. M.; Burygina, L. A.; Sheshina, T. V.; Tiurin, A. A.; Dolgikh, O. Yu, Kazymova, E. V.; Konstantinov, D. Yu, Chumakova, O. A.; Kondriakova, O. V.; Shishkov, K. Yu, Fil, T. S.; Prokofeva, N. A.; Konoval, M. P.; Simonov, A. A.; Bitieva, A. M.; Trostianetckaia, N. A.; Cholponbaeva, M. B.; Kerimbekova, Zh B.; Duyshobayev, M. Y.; Akunov, A. Ch, Kushubakova, N. A.; Melnikov, E. S.; Kim, E. S.; Sherbakov, S. Y.; Trofimov, D. A.; Evdokimov, D. S.; Ayipova, D. A.; Duvanov, I. A.; Abdrakhmanova, A. K.; Aimakhanova, G. T.; Ospanova, Sh O.; Dabylova, G. M.; Tursunova, A. T.; Kaskaeva, D. S.; Tulichev, A. A.; Ashina, E. Yu, Kordukova, V. A.; Barisheva, O. Yu, Egorova, K. E.; Varlamova, D. D.; Kuprina, T. V.; Pakhomova, E. V.; Kurchugina, N. Yu, Frolova, I. A.; Mazalov, K. V.; Subbotin, A. K.; Kamardina, N. A.; Zarechnova, N. V.; Mamutova, E. M.; Smirnova, L. A.; Klimova, A. V.; Shakhgildyan, L. D.; Tokmin, D. S.; Tupitsin, D. I.; Kriukova, T. V.; Rakov, N. A.; Polyakov, D. S..
Russian Journal of Cardiology ; 25(11):98-107, 2020.
Article in Russian | Russian Science Citation Index | ID: covidwho-1094455

ABSTRACT

COVID-19 is a severe infection with high mortality. The concept of the disease has been shaped to a greater extent on the basis of large registers from the USA, Spain, Italy, and China. However, there is no information on the disease characteristics in Caucasian patients. Therefore, we created an international register with the estimated capacity of 5,000 patients - Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (AKTIV SARS-CoV-2), which brought together professionals from the Russian Federation, Republic of Armenia, Republic of Kazakhstan, and Kyrgyz Republic. The article presents the first analysis of the register involving 1,003 patients. It was shown that the most significant difference of the Caucasian population was the higher effect of multimorbidity on the mortality risk vs other registers. More pronounced effect on mortality of such diseases as diabetes, obesity, hypertension, chronic kidney disease, and age over 60 years was also revealed. COVID-19 - тяжелое инфекционное заболевание с высоким риском летального исхода. Представление о болезни во многом сформировано на основании крупных регистров, выполненных в США, Испании, Италии, КНР. Однако к настоящему времени нет данных по особенностям протекания болезни у пациентов евроазиатского региона. В связи с этим был создан международный регистр, расчетная мощность которого составляет 5000 пациентов, “Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS-CoV-2” (AКТИВ SARS-CoV-2), работа в котором объединила специалистов Российской Федерации, Республики Армения, Республики Казахстан и Кыргызской Республики. В статье представлен первый анализ регистра, который включил данные 1003 пациентов. Показано, что самым значимым отличием евроазиатской популяции пациентов оказалось гораздо большее влияние полиморбидности на риск летального исхода в сравнении с другими регистрами, а также более выраженное влияние на риск летального исхода в евроазиатской популяции таких заболеваний, как сахарный диабет, ожирение, артериальная гипертензия, хроническая болезнь почек и возраста старше 60 лет.

SELECTION OF CITATIONS
SEARCH DETAIL